The abstract is read at the publisher; the summary is JClub's.
MUC4 regulatory-region CpG methylation is higher in primary breast tumors than in normal tissue, and metastatic lesions show lower, intermediate methylation across 11 CpG sites.
- Why it matters: MUC4 expression shifts during breast cancer progression, but the epigenetic mechanism in patient samples is unclear.
- What they did: TCGA-BRCA analyses linked MUC4 regulatory methylation to transcript abundance, and 5-aza-2'-deoxycytidine altered MUC4 expression in several breast cancer cell lines. Targeted bisulfite sequencing of an independent cohort compared normal, primary, and metastatic specimens at 11 CpG sites.
- The result: Primary tumors are significantly more methylated than normal at all 11 CpG sites, while metastatic specimens are generally less methylated than primary and intermediate between normal and primary, supporting stage-dependent MUC4 regulation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.